Business
Zhongchao Inc. Partners with a Public Health Foundation to Safeguard Cancer Patients' Health
SHANGHAI, April 24, 2023 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering
About this update from Zhongchao Inc.
[{"type":"text","content":"SHANGHAI, April 24, 2023 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) (\"Zhongchao\" or the \"Company\"), a platform-based internet technology company offering services to patients with cancer and other major diseases, today announced that Shanghai Zhongxin Medical Technology Co., Ltd. (\"Zhongxin\"), of which Zhongchao consolidates the operations and financial results through a series of contractual arrangements, has entered into a service agreement (the \"Agreement\") with Beijing Public Health Foundation (\"BPHF\"), a non-profit organization dedicated to enhancing Chinese citizens' health through public welfare initiatives and aid programs, to work together to develop a patient aid project (the \"Project\")..\nThis Project will donate Trilaciclib Hydrochloride, which is used for protecting bone marrow during chemotherapy, to low-income cancer patients undergoing chemotherapy based on the patient's needs. It aims to provide drug aids for bone marrow protection to mitigate chemotherapy-related adverse reactions and improve the safety of chemotherapy. The parties intend to leverage their respective resources and capabilities to jointly promote the treatment progress, provide medication to improve life quality, and alleviate financial burdens on low-income cancer patients undergoing chemotherapy. Pursuant to the Agreement, the two parties will establish a Project office as the executional organization under the supervision and guidance of BPHF. Zhongxin, leveraging its self-developed patient assistance program technical service platform, is responsible for developing the information system for the Project, verifying patients' medical and economic conditions, recruiting qualified patients, managing drug circulation, addressing patients' related questions, and providing other supports. BPHF is responsible for the supervision, overall management and final approval of the Project, donated medications, and assistance plans. .\nAccording to Cancer Statistics in China and United States, 2022: Profiles, Trends and Determinants from Chinese Medical Journal, in 2022, there would be approximately 4.82 million new cancer cases in China, a vast population in need of chemotherapy. Chemotherapy-induced toxic side effects have an exceptionally high incidence rate. According to an article Consensus of Experts in Integrative Medicine of Tradition...